Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

COVE Moderna/NIH phase 3 (study 301), 2020 NCT04470427

Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=15181) vs. placebo (n=15170)

randomized controlled trial   some concerns about risk of bias

Studied treatment

mRNA-1273 vaccine
100 μg of mRNA-1273 two-dose schedule given one month apart

Control treatment

placebo
saline placebo two-dose schedule given one month apart

Patients

COVID-19 prophylaxis (excluding children)

Method

double blind

100 centres, USA

Randomization was stratified based on age and the presence or absence of risk factors for severe illness for COVID-19

Remark

Moderna study 201 100µg, 2020 NCT04405076

Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=189) vs. placebo (n=186)

randomized controlled trial   risk of bias NA

Studied treatment

mRNA-1273 100µg

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

phase 2a

Remark